1.
Diabetes Metab Syndr
; 14(4): 497, 2020.
Article
in English
| MEDLINE | ID: covidwho-176028
Subject(s)
Betacoronavirus/pathogenicity , Coronavirus Infections/prevention & control , Infection Control/methods , Pandemics/prevention & control , Pneumonia, Viral/prevention & control , Post-Exposure Prophylaxis/standards , Transients and Migrants/psychology , Transients and Migrants/statistics & numerical data , COVID-19 , Coronavirus Infections/epidemiology , Coronavirus Infections/transmission , Coronavirus Infections/virology , Humans , Hydroxychloroquine/standards , Hydroxychloroquine/therapeutic use , India/epidemiology , Pneumonia, Viral/epidemiology , Pneumonia, Viral/transmission , Pneumonia, Viral/virology , Risk Factors , SARS-CoV-2
2.
Antiviral Res
; 177: 104762, 2020 05.
Article
in English
| MEDLINE | ID: covidwho-4426
ABSTRACT
Recent publications have brought attention to the possible benefit of chloroquine, a broadly used antimalarial drug, in the treatment of patients infected by the novel emerged coronavirus (SARS-CoV-2). The scientific community should consider this information in light of previous experiments with chloroquine in the field of antiviral research.